Company intelligence / Profile preview

Lyotropic Therapeutics

Ashland, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Lyotropic Therapeutics developed the LyoCell drug delivery platform, licensed for use in both small and large molecule pharmaceuticals. The platform was applied in drugs advancing to late-stage clinical development for parenteral (injectable) use, including high-concentration dantrolene for malignant hyperthermia; later, rights to this platform were licensed or sold to Eagle Pharmaceuticals and Particle Sciences. There are no recent independent clinical updates; company may now be defunct or fully absorbed.

Therapeutic areas: OtherNeurologyRare Diseases
Modalities: Small moleculeBiologicLipid nanoparticle delivery therapy
Industry: Biotech

Partnerships

Eagle PharmaceuticalsParticle SciencesElan Pharma International (original licensor for some IP)

Beyond the preview

Go deeper on Lyotropic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyotropic Therapeutics.

Explore the full profile